Aura Continued Phase 3 in Choroidal Melanoma, Phase 1b/2 in Non-Muscle Invasive Bladder Cancer

 Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to Fund Operations into the First Half of 2027

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the second quarter ended June 30, 2025, and provided recent business highlights.

“We continued to focus on execution in our clinical programs in the second quarter, including our ongoing global Phase 3 CoMpass trial in early choroidal melanoma and our Phase 1b/2 trial in NMIBC,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura. “With the successful completion of our recent equity financing, we believe we are well positioned to advance the clinical development of bel-sar in our ocular and urologic oncology programs, where we believe our unique mechanism of action has the potential to meaningfully impact the lives of patients.”

https://www.globenewswire.com/news-release/2025/08/13/3132426/0/en/Aura-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Business-Highlights.html